Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb;32(2):335-41.
doi: 10.2337/dc08-1478. Epub 2008 Oct 28.

Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels

Affiliations

Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels

Kristina M Utzschneider et al. Diabetes Care. 2009 Feb.

Erratum in

  • Diabetes Care. 2009 Jul;32(7):1355

Abstract

Objective: We sought to determine whether an oral disposition index (DI(O)) predicts the development of diabetes over a 10-year period. First, we assessed the validity of the DI(O) by demonstrating that a hyperbolic relationship exists between oral indexes of insulin sensitivity and beta-cell function.

Research design and methods: A total of 613 Japanese-American subjects (322 men and 291 women) underwent a 75-g oral glucose tolerance test (OGTT) at baseline, 5 years, and 10 years. Insulin sensitivity was estimated as 1/fasting insulin or homeostasis model assessment of insulin sensitivity (HOMA-S). Insulin response was estimated as the change in insulin divided by change in glucose from 0 to 30 min (DeltaI(0-30)/DeltaG(0-30)).

Results: DeltaI(0-30)/DeltaG(0-30) demonstrated a curvilinear relationship with 1/fasting insulin and HOMA-S with a left and downward shift as glucose tolerance deteriorated. The confidence limits for the slope of the log(e)-transformed estimates included -1 for DeltaI(0-30)/DeltaG(0-30) versus 1/fasting insulin for all glucose tolerance groups, consistent with a hyperbolic relationship. When HOMA-S was used as the insulin sensitivity measure, the confidence limits for the slope included -1 only for subjects with normal glucose tolerance (NGT) or impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) but not diabetes. On the basis of this hyperbolic relationship, the product of DeltaI(0-30)/DeltaG(0-30) and 1/fasting insulin was calculated (DI(O)) and decreased from NGT to IFG/IGT to diabetes (P < 0.001). Among nondiabetic subjects at baseline, baseline DI(O) predicted cumulative diabetes at 10 years (P < 0.001) independent of age, sex, BMI, family history of diabetes, and baseline fasting and 2-h glucose concentrations.

Conclusions: The DI(O) provides a measure of beta-cell function adjusted for insulin sensitivity and is predictive of development of diabetes over 10 years.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The computed slopes (——) and 95% CIs for the slopes (– – –) for ln(ΔI0–30/ΔG0–30) versus ln(1/fasting insulin) are plotted for subjects with NGT (slope −0.87 [95% CI −1.13 to −0.61]) (A), IGM (−0.84 [−1.05 to −0.63]) (B), and diabetes (DM) (−0.76 [−1.16 to −0.35]) (C). D: The hyperbolic curves for NGT, IGM, and diabetes, assuming a slope of −1, are plotted for ΔI0–30/ΔG0–30 versus 1/fasting insulin.
Figure 2
Figure 2
A: The DIO (ΔI0–30/ΔG0–30 × 1/fasting insulin) decreases from NGT to IGM to diabetes (DM) (median [interquartile range]). B: The logarithmic means for baseline ΔI0–30/ΔG0–30 and 1/fasting insulin values are plotted for subjects with NGT (▪ and □) and IGM (• and ○) as nonprogressors (▪ and •) and progressors (□ and ○) relative to the hyperbolic curves. Progressors had lower β-cell function at baseline. C: The number of subjects who developed diabetes over the 10-year follow-up period by quintiles of baseline DIO. D: ROC curves comparing ability of baseline ΔI0–30/ΔG0–30 (dotted line), 1/fasting insulin (dashed line), and DIO (solid line) to predict cumulative diabetes at 10 years.

Comment in

References

    1. Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19, 2003 - PubMed
    1. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467, 1981 - PMC - PubMed
    1. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al.: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672, 1993 - PubMed
    1. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796–2803, 2002 - PubMed
    1. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS: Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520–527, 1995 - PMC - PubMed

Publication types